Cabometyx FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 22, 2021.
FDA Approved: Yes (First approved April 25, 2016)
Brand name: Cabometyx
Generic name: cabozantinib
Dosage form: Tablets
Company: Exelixis, Inc.
Treatment for: Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC).
- Cabometyx is indicated for the treatment of:
- patients with advanced renal cell carcinoma (RCC)
- patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab
- patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
- adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
- Cabometyx tablets are taken orally, once daily.
- Common side effects include diarrhea, fatigue, Palmar-Plantar Erythrodysesthesia (PPE), decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation.
Development timeline for Cabometyx
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
